Skip to main content

Postherpetic Neuralgia

13
Pipeline Programs
14
Companies
17
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
8
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 16 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
4 programs
3
1
pregabalinPhase 41 trial
ADL5747Phase 21 trial
T-62Phase 22 trials
pregabalinPhase 21 trial
Active Trials
NCT01058642Terminated41Est. Dec 2010
NCT00506610Withdrawn0
NCT00809679Terminated19Est. Jun 2009
+2 more trials
MSD
MSDIreland - Ballydine
2 programs
1
1
EtoricoxibPhase 4Small Molecule1 trial
MK-8291Phase 11 trial
Active Trials
NCT02336555Completed35Est. Feb 2016
NCT01264237Unknown120Est. Apr 2012
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
EtoricoxibPhase 4Small Molecule
MK-8291Phase 1
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Botulinum Toxin Type APhase 21 trial
Active Trials
NCT00168441Completed117Est. Jun 2005
Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
1 program
1
ONO-1110Phase 21 trial
Active Trials
NCT06708416Active Not Recruiting140Est. Aug 2026
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
RetigabinePhase 21 trial
Active Trials
NCT00612105Completed187Est. Dec 2009
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
1
V116517 50-mg tabletsPhase 21 trial
Active Trials
NCT01688947Completed105Est. Apr 2014
NeuroDawn Pharmaceutical
1 program
1
Y-4 tablesPhase 21 trial
Active Trials
NCT07275762Recruiting160Est. Nov 2026
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
SPM 927PHASE_21 trial
SPM927/LacosamidePHASE_21 trial
Active Trials
NCT00238511CompletedEst. Jan 2005
NCT00861068Completed44Est. Jan 2003
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Active electrostimulationN/A1 trial
Active Trials
NCT06290661Recruiting60Est. Dec 2026
Bial
BialPortugal - Coronado
1 program
Eslicarbazepine acetatePHASE_21 trial
Active Trials
NCT00981227Completed567Est. Jan 2009
Xenon Pharmaceuticals
1 program
XPF-002PHASE_21 trial
Active Trials
NCT01195636Completed70Est. Mar 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizerpregabalin
MSDEtoricoxib
NeuroDawn PharmaceuticalY-4 tables
Ono PharmaceuticalONO-1110
Purdue PharmaV116517 50-mg tablets
Xenon PharmaceuticalsXPF-002
PfizerADL5747
PfizerT-62
Pfizerpregabalin
BialEslicarbazepine acetate
Bausch HealthRetigabine
AbbVieBotulinum Toxin Type A
UCB PharmaSPM 927
UCB PharmaSPM927/Lacosamide
MSDMK-8291

Showing 15 of 16 trials with date data

Clinical Trials (17)

Total enrollment: 1,746 patients across 17 trials

Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia

Start: Oct 2012Est. completion: Jun 20139 patients
Phase 4Terminated
NCT01264237MSDEtoricoxib

Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain

Start: Mar 2011Est. completion: Apr 2012120 patients
Phase 4Unknown

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

0
Phase 2Withdrawn

Y-4 to Treat the Postherpetic Neuralgia

Start: Feb 2026Est. completion: Nov 2026160 patients
Phase 2Recruiting

A Study of ONO-1110 in Patients With Postherpetic Neuralgia

Start: Feb 2025Est. completion: Aug 2026140 patients
Phase 2Active Not Recruiting
NCT01688947Purdue PharmaV116517 50-mg tablets

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Start: Sep 2012Est. completion: Apr 2014105 patients
Phase 2Completed

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Start: Aug 2010Est. completion: Mar 201170 patients
Phase 2Completed

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Start: Jan 2010Est. completion: Dec 201041 patients
Phase 2Terminated

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

Start: Dec 2008Est. completion: Jun 200919 patients
Phase 2Terminated

A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia

Start: Apr 2008Est. completion: Dec 200872 patients
Phase 2Completed
NCT00981227BialEslicarbazepine acetate

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia

Start: Nov 2007Est. completion: Jan 2009567 patients
Phase 2Completed

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Start: Oct 2007Est. completion: Dec 2009187 patients
Phase 2Completed
NCT00168441AbbVieBotulinum Toxin Type A

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Start: Jun 2004Est. completion: Jun 2005117 patients
Phase 2Completed

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Start: Nov 2002Est. completion: Jan 2005
Phase 2Completed
NCT00861068UCB PharmaSPM927/Lacosamide

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Start: Feb 2002Est. completion: Jan 200344 patients
Phase 2Completed

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

Start: Mar 2015Est. completion: Feb 201635 patients
Phase 1Completed
NCT06290661UNION therapeuticsActive electrostimulation

Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.

Start: Feb 2023Est. completion: Dec 202660 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,746 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.